Leadership Transition Details

Aarti Drugs Limited announced significant leadership changes approved by the Board of Directors at its meeting held on July 31, 2026. The transition is effective from October 1, 2026, and was made on the recommendation of the Nomination and Remuneration Committee.

Specific Role Changes

  • Shri Rashesh C. Gogri elevated to Chairman in addition to his existing role as Managing Director
  • Shri Adhish P. Patil appointed as Managing Director
  • Shri Prakash M. Patil will retire as Chairman, Managing Director & Chief Executive Officer with effect from the close of business hours on September 30, 2026

Executive Backgrounds

Shri Rashesh C. Gogri has been associated with the Company as Managing Director since September 2014, having earlier served as Whole-time Director from October 2012. He holds a degree in Production Engineering from Mumbai University and brings more than 27 years of experience in Production, Marketing and Project Implementation in the chemical and pharmaceutical industry. He also serves as Vice-Chairman & Managing Director of Aarti Industries Limited and as Chairman of Aarti Pharmalabs Limited.

Shri Adhish P. Patil has been associated with the Company as Chief Financial Officer since April 2014 and has led the Company's finance, technical and commercial functions. He holds a Bachelor of Engineering (IT) degree from Mumbai University and an MBA in Finance and Marketing from the University of Florida's Warrington College of Business Administration, where he graduated as a gold medallist. He has been named to the 'Top 100 CFOs India 2014' list and, in 2024, to the 'Top 20 CFOs in India' list published by StartupLanes. His appointment as Managing Director is subject to the approval of shareholders at the ensuing Annual General Meeting.

Management Commentary

Shri Prakash M. Patil, Chairman, stated: "It has been the privilege of my professional life to help build Aarti Drugs from its earliest days into the company it is today. I have complete confidence in Rashesh and Adhish, and in the strength of the team we have built together over the years. I look forward to continuing to contribute by providing guidance, strategic support and ensuring smooth transition, while supporting the Company's next phase of growth."

Shri Rashesh C. Gogri, Chairman-designate, stated: "Aarti Drugs has always stood for scientific rigour, quality and dependability – values I have had the privilege of helping shape over the past decade as Managing Director. As Chairman, I look forward to build on this foundation, deepen our capabilities across our API and formulations businesses, and pursue the opportunities ahead of us with the same discipline that has always defined this Company."

Shri Adhish P. Patil, Managing Director-designate, stated: "I am honoured by the Board's confidence in me. Having spent over a decade with Aarti Drugs across finance and operations, I have seen first-hand the strength of our people, our manufacturing capabilities and our customer as well as other stakeholder relationships. I look forward to working with the entire team to sharpen our execution, deepen our competitiveness and create lasting value for all our stakeholders."

Strategic Implications

The leadership transition does not alter the Company's long-term strategic direction. This realignment is aimed to create a natural evolution of ADL's governance framework – one that balances continuity with renewal. The change reflects a well-structured approach to succession planning and long-term value creation, ensuring that experienced stewardship and fresh strategic thinking work in tandem as Aarti Drugs scales its operations.

Company Background

Aarti Drugs Limited was established in 1984 and forms part of $6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC). The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and produces Formulations with its wholly-owned subsidiary-Pinnacle Life Science Private Limited. The Company has total 14 manufacturing facilities (10 in Maharashtra, 3 in Gujarat, and 1 in Himachal Pradesh).